Table 1.
Baseline patient, disease and donor characteristics of the T-replete RIC HSCT cohort
| N | % | |
|---|---|---|
| Total | 688 | 100 |
| Patient Age, median (range) | 57 (18,74) | |
| Patient Sex | ||
| Male | 437 | 63.5 |
| Female | 251 | 36.5 |
| Donor Age, median (range) | 39 (12, 73) | |
| Donor Sex | ||
| Male | 400 | 58.1 |
| Female | 288 | 41.9 |
| Patient-Donor Sex Match | ||
| Female-Female | 117 | 17 |
| Female-Male | 134 | 19.5 |
| Male-Female | 171 | 24.9 |
| Male-Male | 266 | 38.7 |
| Diagnosis | ||
| AML | 193 | 28.1 |
| CLL, SLL, PLL | 113 | 16.4 |
| CML | 22 | 3.2 |
| Hodgkin Disease | 52 | 7.6 |
| MM/PCD | 32 | 4.7 |
| ALL | 19 | 2.8 |
| MDS | 94 | 13.7 |
| MPD | 21 | 3.1 |
| Mixed MDS/MPD | 2 | 0.3 |
| NHL | 140 | 20.3 |
| Donor HLA-matching | ||
| 8/8 Matched unrelated | 394 | 57.3 |
| 8/8 Matched related | 242 | 35.2 |
| 7/8 Mismatch unrelated | 49 | 7.1 |
| 7/8 Mismatch related | 3 | 0.4 |
| Stem Cell Source | ||
| Bone marrow | 20 | 2.9 |
| Peripheral blood | 668 | 97.1 |
| Disease Risk Index | ||
| Low | 159 | 23.1 |
| Intermediate | 362 | 52.6 |
| High | 155 | 22.5 |
| Very high | 12 | 1.7 |
| Patient-Donor CMV status | 230 | 33.4 |
| Negative | 230 | 33.4 |
| Any Positive | 458 | 66.6 |
| Acute GVHD prophylaxis | ||
| CNI+Sirolimus based | 483 | 70.2 |
| CNI+Non-Sirolimus based | 193 | 27.9 |
| Other | 12 | 1.7 |
| Prior allogeneic transplant | 114 | 16.6 |
| Conditioning Regimen Intensity | ||
| Bu1 | 559 | 81.3 |
| Bu2 | 129 | 18.8 |
| Year of Transplantation, range | 2002-2010 | |
AML: acute myeloid leukemia, ALL: acute lymphoid leukemia, CLL/SLL/PLL: chronic lymphocytic leukemia/small lymphocytic leukemia/pro-lymphocytic leukemia; CML: chronic myeloid leukemia, MM/PCD: multiple myeloma/plasma cell dyscrasia, MDS: myelodysplastic syndromes, MPD: myeloproliferative diseases, NHL: non-Hodgkin lymphoma, Bu1: once-daily busulfan RIC, Bu2: twice-daily busulfan RIC, CNI: calcineurin inhibitor